This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Time for Drug Channels ’ annual update on pricing at the largest pharmaceuticalmanufacturers. Click here to see the original post from May 2022.
Time for Drug Channels ’ annual update on pricing at the largest pharmaceuticalmanufacturers. When rebates and discounts were factored in, brand-name drugprices again declined—or grew slowly—in 2022. But for now, the 2022 data provide fresh inconvenient facts for the drugpricing flat earthers (#DPFE).
This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channels Update: 340B Controversies and Outlook. Time for Drug Channels ' annual update on pricing at six of the largest pharmaceuticalmanufacturers—Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, and Sanofi.
Pharmacies and PBMs, Examining $683 Billion Market Review pricing/license options and download the full 2025 report Order before March 31, 2025 to receive special discounted pricing! drugpricing, reimbursement, and dispensing system. prescription drug channels. Want to bundle the report with DCIs video webinars ?
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content